The panel included the KRAS, NRAS and BRAF genes that may be used to determine the eligibility of colorectal cancer (CRC) patients for targeted anti-EGFR treatment, as well as to establish prognosis at any stage of the disease (Sepulveda et al., 2017). The gene discussed is BRAF; the disease is colorectal carcinoma.